• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2005 - 2018年纽约州社会决定因素对原发性酒精使用问题患者与阿片类药物使用障碍患者阿片类药物依赖药物处方模式的影响差异

Differences in prescribing patterns of opioid dependence drugs among patients with primary alcohol use problems and opioid use disorders within New York State by social determinant factors, 2005-2018.

作者信息

Lu Chi-Hua, Su Hsuan-Yun, Falls Zackary, Jacobs David M, Zhang Qiuyi, Gibson Walter, Jette Gail, Paul Debanjan, Elkin Peter L, Leonard Kenneth E, Bednarczyk Edward M

出版信息

J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102258. doi: 10.1016/j.japh.2024.102258. Epub 2024 Sep 27.

DOI:10.1016/j.japh.2024.102258
PMID:39343100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912015/
Abstract

BACKGROUND

The increase in alcohol use problems and opioid use disorder (OUD) highlights the need for research on effective medication treatments for patients with dual diagnoses.

OBJECTIVES

This study analyzed trends and social disparities in prescribing OUD medications for patients who initially had alcohol use problems and later received their first OUD diagnosis.

METHODS

This study used merged data from the New York State Office of Addiction Services and Supports and the Medicaid to analyze individuals aged 18 years and older who initially had primary alcohol use problems and later had OUD for the first time between 2005 and 2018. It examined the rates of new buprenorphine and naltrexone prescriptions across various demographic and socioeconomic groups.

RESULTS

Among 27,029 clients, the average rate of new buprenorphine was 64.23 per 1000 clients (95% CI 61.30-67.15), with upward trends. The 18-35 age group had the highest buprenorphine utilization (111.48 per 1000 clients) and highest increase rates compared with other age groups. The white non-Hispanic group had the highest rates of buprenorphine (119.23 per 1000 clients) and showed larger increase over time compared with other race or ethnicity groups. Disabled patients showed slower increasing rates of buprenorphine than other groups. Upward trends were observed in naltrexone. All observed differences were statistically significant (P < 0.05).

CONCLUSIONS

Trends showed increased use of OUD medications, with varying rates of buprenorphine utilization across different ages, races, and employment statuses. Despite this, the rates of receiving new buprenorphine remained low, suggesting a need for innovative methods to expand access to treatments.

摘要

背景

酒精使用问题和阿片类物质使用障碍(OUD)的增加凸显了对双重诊断患者有效药物治疗进行研究的必要性。

目的

本研究分析了最初有酒精使用问题且后来首次被诊断为OUD的患者在开具OUD药物方面的趋势和社会差异。

方法

本研究使用了纽约州成瘾服务与支持办公室和医疗补助计划的合并数据,以分析2005年至2018年期间18岁及以上最初有原发性酒精使用问题且后来首次出现OUD的个体。研究考察了不同人口统计学和社会经济群体中新的丁丙诺啡和纳曲酮处方率。

结果

在27029名客户中,新的丁丙诺啡平均处方率为每1000名客户64.23例(95%置信区间61.30 - 67.15),呈上升趋势。18 - 35岁年龄组的丁丙诺啡使用率最高(每1000名客户111.48例),与其他年龄组相比增长率也最高。非西班牙裔白人组的丁丙诺啡使用率最高(每1000名客户119.23例),与其他种族或族裔群体相比随时间的增长幅度更大。残疾患者的丁丙诺啡增长率低于其他群体。纳曲酮呈上升趋势。所有观察到的差异均具有统计学意义(P < 0.05)。

结论

趋势表明OUD药物的使用有所增加,不同年龄、种族和就业状况的丁丙诺啡使用率各不相同。尽管如此,新的丁丙诺啡接受率仍然较低,这表明需要创新方法来扩大治疗的可及性。

相似文献

1
Differences in prescribing patterns of opioid dependence drugs among patients with primary alcohol use problems and opioid use disorders within New York State by social determinant factors, 2005-2018.2005 - 2018年纽约州社会决定因素对原发性酒精使用问题患者与阿片类药物使用障碍患者阿片类药物依赖药物处方模式的影响差异
J Am Pharm Assoc (2003). 2025 Jan-Feb;65(1):102258. doi: 10.1016/j.japh.2024.102258. Epub 2024 Sep 27.
2
Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type.按种族、民族和保险类型划分的丁丙诺啡和纳曲酮用于阿片类物质使用障碍的情况
JAMA Netw Open. 2025 Jun 2;8(6):e2518493. doi: 10.1001/jamanetworkopen.2025.18493.
3
Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama.阿拉巴马州阿片类药物使用障碍患者开处丁丙诺啡处方的障碍和机会调查。
J Addict Dis. 2024 Oct-Dec;42(4):410-417. doi: 10.1080/10550887.2023.2247950. Epub 2023 Aug 31.
4
Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization.丁丙诺啡日剂量与紧急医疗保健利用的关联。
JAMA Netw Open. 2024 Sep 3;7(9):e2435478. doi: 10.1001/jamanetworkopen.2024.35478.
5
Trends in Access to Medications for Opioid Use Disorder.阿片类物质使用障碍药物获取趋势。
JAMA Health Forum. 2025 Apr 4;6(4):e250393. doi: 10.1001/jamahealthforum.2025.0393.
6
Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.评估兴奋剂使用对两项临床试验和真实世界人群中丁丙诺啡和纳曲酮延伸释放制剂起始使用的影响。
Addict Sci Clin Pract. 2023 Feb 14;18(1):11. doi: 10.1186/s13722-023-00364-3.
7
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.州许可的专业物质使用治疗计划中使用丁丙诺啡的障碍和促进因素:对项目领导层的调查。
J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17.
8
Trend in Prescription Medication Utilization for Opioid Use Disorder and Alcohol Use Disorder From 2015 to 2021: A Population-wide Study in a Canadian Province.2015 年至 2021 年阿片类药物使用障碍和酒精使用障碍处方药物使用趋势:加拿大一省的全人群研究。
J Addict Med. 2024;18(6):683-688. doi: 10.1097/ADM.0000000000001348. Epub 2024 Jul 16.
9
Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.美沙酮与丁丙诺啡治疗阿片类物质使用障碍的有效性:前瞻性队列研究数据的二次分析
BMJ Open. 2025 Jun 17;15(6):e095645. doi: 10.1136/bmjopen-2024-095645.
10
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.美国药物治疗阿片类药物使用障碍的药物、种族/民族和性别与治疗保留的系统评价和荟萃分析。
Addict Behav. 2022 Jan;124:107113. doi: 10.1016/j.addbeh.2021.107113. Epub 2021 Sep 6.

本文引用的文献

1
Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies.参与医疗补助计划的社区零售药店配给丁丙诺啡的障碍。
JAMA Health Forum. 2024 May 3;5(5):e241077. doi: 10.1001/jamahealthforum.2024.1077.
2
Relationships Between Stigma, Risk Tolerance, and Buprenorphine Dispensing Intentions Among Community-Based Pharmacists: Results From a National Sample.社区药师的污名化、风险承受能力与丁丙诺啡配药意愿之间的关系:来自全国样本的结果。
Subst Use Addctn J. 2024 Apr;45(2):211-221. doi: 10.1177/29767342231215178. Epub 2024 Jan 4.
3
A cohort of patients in New York State with an alcohol use disorder and subsequent treatment information - A merging of two administrative data sources.纽约州患有酒精使用障碍及后续治疗信息的患者队列 - 两个行政数据源的合并。
J Biomed Inform. 2023 Aug;144:104443. doi: 10.1016/j.jbi.2023.104443. Epub 2023 Jul 16.
4
Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.与开具丁丙诺啡治疗阿片类药物使用障碍相关的认知、政策和实践:一项针对社区药剂师的全国性调查。
J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):252-260.e6. doi: 10.1016/j.japh.2022.08.017. Epub 2022 Aug 24.
5
Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.《2000 年《药物成瘾治疗法》豁免:开处丁丙诺啡的障碍和促进因素调查及临床医生认知》
JAMA Netw Open. 2022 May 2;5(5):e2212419. doi: 10.1001/jamanetworkopen.2022.12419.
6
Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior.基于治疗利用行为,美国人口普查区在获得阿片类物质使用障碍药物治疗方面的地理差异。
Soc Sci Med. 2022 Jun;302:114992. doi: 10.1016/j.socscimed.2022.114992. Epub 2022 Apr 28.
7
Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.2019 年美国需要阿片类药物治疗的青少年和成年人中,阿片类药物使用障碍药物治疗的使用情况。
JAMA Netw Open. 2022 Mar 1;5(3):e223821. doi: 10.1001/jamanetworkopen.2022.3821.
8
Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.早期使用丁丙诺啡-纳洛酮治疗阿片类药物使用障碍可减少阿片类药物过量、急诊就诊次数和医疗保健费用,与晚期使用相比。
Am J Drug Alcohol Abuse. 2022 Mar 4;48(2):217-225. doi: 10.1080/00952990.2021.1981358. Epub 2021 Nov 15.
9
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.种族不平等在阿片类药物使用障碍的药物治疗中:探索使用的潜在促进因素和障碍。
Drug Alcohol Depend. 2021 Oct 1;227:108927. doi: 10.1016/j.drugalcdep.2021.108927. Epub 2021 Jul 28.
10
Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.美国 11 个州的医疗补助受助人在 2014-2018 年期间使用药物治疗阿片类药物使用障碍的情况。
JAMA. 2021 Jul 13;326(2):154-164. doi: 10.1001/jama.2021.7374.